The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kemp, R. A.
Right arrow Articles by Ronchese, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kemp, R. A.
Right arrow Articles by Ronchese, F.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2001, 167: 6497-6502.
Copyright © 2001 by The American Association of Immunologists

Tumor-Specific Tc1, But Not Tc2, Cells Deliver Protective Antitumor Immunity1

Roslyn A. Kemp and Franca Ronchese2

Malaghan Institute of Medical Research, Wellington School of Medicine, Wellington, New Zealand

We investigated whether secretion of multiple cytokines by CD8+ T cells is associated with improved protection against tumor challenge. We show that antitumor immunity induced by immunization with dendritic cells and a MHC class I-binding tumor peptide are dependent on secretion of IFN-{gamma} but not IL-4 or IL-5 by host cells. To further address the role of IL-4 and IL-5 in antitumor immunity, tumor-specific TCR-transgenic CD8+ T cells were activated in vitro to generate cytotoxic T (Tc) 1 cells that secrete high IFN-{gamma} and no IL-4 or IL-5 or Tc2 cells that secrete IL-4, IL-5, and some IFN-{gamma}. Both cell types killed target cells in vitro. Tc1 and Tc2 cells were adoptively transferred into syngeneic hosts, and their ability to protect against tumor challenge was compared. Tc1 cells were able to significantly delay tumor growth, whereas Tc2 cells or Tc2 cells from IFN-{gamma}-/- donors had no effect. This was due to neither the inability of Tc2 cells to survive in vivo or to migrate to the tumor site nor their inability to secrete IL-4 and/or IL-5 in the presence of limiting amounts of anti-CD3. However, IFN-{gamma} secretion by Tc2 cells was triggered inefficiently by restimulation with Ag compared with anti-CD3. We conclude that the ability to secrete "type 2" cytokines, and cytotoxic ability, have a limited role in antitumor immune responses mediated by CD8+ T cells, whereas the capacity to secrete high amounts of IFN-{gamma} remains the most critical antitumor effector mechanism in vivo.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Ueda, G. Kohanbash, K. Sasaki, M. Fujita, X. Zhu, E. R. Kastenhuber, H. A. McDonald, D. M. Potter, R. L. Hamilton, M. T. Lotze, et al.
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
PNAS, June 30, 2009; 106(26): 10746 - 10751.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. S. Umeshappa, H. Huang, Y. Xie, Y. Wei, S. J. Mulligan, Y. Deng, and J. Xiang
CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses
J. Immunol., January 1, 2009; 182(1): 193 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Minkis, D. G. Kavanagh, G. Alter, D. Bogunovic, D. O'Neill, S. Adams, A. Pavlick, B. D. Walker, M. A. Brockman, R. T. Gandhi, et al.
Type 2 Bias of T Cells Expanded from the Blood of Melanoma Patients Switched to Type 1 by IL-12p70 mRNA-Transfected Dendritic Cells
Cancer Res., November 15, 2008; 68(22): 9441 - 9450.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Sasaki, X. Zhao, A. D. Pardee, R. Ueda, M. Fujita, S. Sehra, M. H. Kaplan, L. P. Kane, H. Okada, and W. J. Storkus
Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo
J. Immunol., July 1, 2008; 181(1): 104 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Sasaki, X. Zhu, C. Vasquez, F. Nishimura, J. E. Dusak, J. Huang, M. Fujita, A. Wesa, D. M. Potter, P. R. Walker, et al.
Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors
Cancer Res., July 1, 2007; 67(13): 6451 - 6458.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Ohta, E. Gorelik, S. J. Prasad, F. Ronchese, D. Lukashev, M. K. K. Wong, X. Huang, S. Caldwell, K. Liu, P. Smith, et al.
A2A adenosine receptor protects tumors from antitumor T cells
PNAS, August 29, 2006; 103(35): 13132 - 13137.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Iezzi, A. Boni, E. Degl'Innocenti, M. Grioni, M. T. S. Bertilaccio, and M. Bellone
Type 2 Cytotoxic T Lymphocytes Modulate the Activity of Dendritic Cells Toward Type 2 Immune Responses
J. Immunol., August 15, 2006; 177(4): 2131 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Yang, S. P. Huck, R. S. McHugh, I. F. Hermans, and F. Ronchese
Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo
PNAS, January 3, 2006; 103(1): 147 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Olver, P. Groves, K. Buttigieg, E. S. Morris, M. L. Janas, A. Kelso, and N. Kienzle
Tumor-Derived Interleukin-4 Reduces Tumor Clearance and Deviates the Cytokine and Granzyme Profile of Tumor-Induced CD8+ T Cells
Cancer Res., January 1, 2006; 66(1): 571 - 580.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
D. M. Jelley-Gibbs, J. P. Dibble, S. Filipson, L. Haynes, R. A. Kemp, and S. L. Swain
Repeated stimulation of CD4 effector T cells can limit their protective function
J. Exp. Med., April 4, 2005; 201(7): 1101 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Kienzle, S. Olver, K. Buttigieg, P. Groves, M. L. Janas, A. Baz, and A. Kelso
Progressive Differentiation and Commitment of CD8+ T Cells to a Poorly Cytolytic CD8low Phenotype in the Presence of IL-4
J. Immunol., February 15, 2005; 174(4): 2021 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang
Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern
Cancer Res., February 1, 2005; 65(3): 1063 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
J. M. Roberts, J. Yang, and F. Ronchese
IL-4 deficiency does not impair the ability of dendritic cells to initiate CD4+ and CD8+ T cell responses in vivo
Int. Immunol., October 1, 2004; 16(10): 1451 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. A. Kemp, T. J. Powell, D. W. Dwyer, and R. W. Dutton
Cutting Edge: Regulation of CD8+ T Cell Effector Population Size
J. Immunol., September 1, 2004; 173(5): 2923 - 2927.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. A. Hollenbaugh, J. Reome, M. Dobrzanski, and R. W. Dutton
The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis
J. Immunol., August 1, 2004; 173(3): 1738 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
J. A. DeVoti, B. M. Steinberg, D. W. Rosenthal, L. Hatam, A. Vambutas, A. L. Abramson, M. J. Shikowitz, and V. R. Bonagura
Failure of Gamma Interferon but Not Interleukin-10 Expression in Response to Human Papillomavirus Type 11 E6 Protein in Respiratory Papillomatosis
Clin. Vaccine Immunol., May 1, 2004; 11(3): 538 - 547.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. A. O'Mara and P. M. Allen
Pulmonary Tumors Inefficiently Prime Tumor-Specific T Cells
J. Immunol., January 1, 2004; 172(1): 310 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. A. Holly, C. A. Eberle, and P. M. Bracci
Prior History of Allergies and Pancreatic Cancer in the San Francisco Bay Area
Am. J. Epidemiol., September 1, 2003; 158(5): 432 - 441.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Woodberry, J. Gardner, S. L. Elliott, S. Leyrer, D. M. Purdie, P. Chaplin, and A. Suhrbier
Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias
J. Immunol., March 1, 2003; 170(5): 2599 - 2604.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, M. I. Nishimura, and D. J. Cole
Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity
J. Immunol., February 1, 2003; 170(3): 1209 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Schwaiger, A. M. Wolf, P. Robatscher, B. Jenewein, and B. Grubeck-Loebenstein
IL-4-Producing CD8+ T Cells with a CD62L++(bright) Phenotype Accumulate in a Subgroup of Older Adults and Are Associated with the Maintenance of Intact Humoral Immunity in Old Age
J. Immunol., January 1, 2003; 170(1): 613 - 619.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-J. Malmberg, R. Lenkei, M. Petersson, T. Ohlum, F. Ichihara, B. Glimelius, J.-E. Frodin, G. Masucci, and R. Kiessling
A Short-Term Dietary Supplementation of High Doses of Vitamin E Increases T Helper 1 Cytokine Production in Patients with Advanced Colorectal Cancer
Clin. Cancer Res., June 1, 2002; 8(6): 1772 - 1778.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.